Interview with Patricia Lanssiers, Managing Director, Eli Lilly BeLux
Since 1969, Eli Lilly & Company has been investing in Belgium. Can you give our readers a brief overview of the company’s history here and highlight some of your most…
Address: Rue de lEtuve 52 bte 1 1000 Brussels Belgium
Tel: +32 (0)2 548 84 84
Web: http://www.lilly.be/Nitro/
Eli Lilly is a specialty pharmaceutical company entirely dedicated to innovation. Today, we are developing drugs in the first or best in class.
Our main task is to meet the needs of patients. To this end, we discover and design drugs at the forefront of their therapeutic area and we disseminate information on health, in order to solve health problems which are often difficult and complex.
Our research and development is mainly in the following therapeutic areas:
Oncology
Endocrinology
Central nervous system
Cardiovascular
Urology
Since 1969, Eli Lilly & Company has been investing in Belgium. Can you give our readers a brief overview of the company’s history here and highlight some of your most…
Writing in DIA’s Global Forum magazine for June 2024, the organization’s Vedran Raguz reviews some of the key takeaways from DIA Europe 2024, namely the need for increased collaboration, alignment…
Founded in 1996 to coordinate and promote HIV vaccine development, IAVI has had a major impact across HIV vaccine development efforts, capacity building in low- and middle-income countries, advocacy work,…
PharmaBoardroom was delighted to attend DIA Europe 2024 in Brussels earlier this month, bringing together a veritable who’s-who of the European and global regulatory community. The politicians, regulators, payers, patient…
Belgium, one of Europe’s most important countries for biopharmaceutical production and R&D, assumed presidency of the Council of the European Union on the first of January. As part of its…
A new piece in the January 2023 edition of DIA’s Global Forum magazine lays out how a new coalition aims to transform the landscape for rare disease treatments in Europe…
UCB has been undergoing a far-reaching digital business transformation, integrating novel approaches across its R&D organisation, including Computer-Aided Drug Design (CADD) and AI, while striving to maintain a patient-centric focus.…
Pfizer’s David Isom and Monica Mihedji, writing in the November 2023 edition of the DIA’s Global Forum magazine, examine how the European Medicines Agency is attempting to integrate the use…
Encircled by heavyweight life sciences powerhouses of the likes of Germany, France and Switzerland, plucky Belgium nonetheless continues to astonish and project considerable influence when it comes to its abilities…
The European Coalition for Access to Comprehensive Genomic Profiling (ECGP) is a new initiative made up of industry association the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), molecular diagnostics firms Exact…
Janssen has the lofty aim of reaching USD 60bn dollars in sales by 2025, an 8bn increase on the 2021 figure, despite some high-profile losses of exclusivity and the spin-off…
There have been both ups and downs in AbbVie’s recent history. After proving its staying power with the celebration of its 10-year anniversary as an independent company spun off from…
Representatives of Belgian associations for innovative pharma, generics and biosimilars, medtech, OTC, biotech, hospitals, and medical professionals share their key agenda priorities. These include where they feel that change is…
See our Cookie Privacy Policy Here
